A dose blocked-randomized, double-blind, placebo controlled, single and multiple dosing, dose-escalation phase I clinical trial to investigate the safety, tolerability, pharmacokinetic/pharmacodynamics characteristics and food effect of HSG4112 after oral administration in healthy and obese male subjects
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs HSG 4112 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- 28 Jun 2018 New trial record
- 29 May 2018 According to a Glaceum Inc. media release, the Korean Ministry of Food and Drug Safety (MFDS) approved the IND for the initiation of clinical trials for HSG4112.
- 28 May 2018 According to a Glaceum Inc. media release, the trial will be conducted at Seoul National University Hospital until the first quarter 2019.